LAG3 and lung carcinoma: Additionally, the pioneering simultaneous imaging of LAG‐3 and PD‐L1 allows for distinguishing various lung cancer immunotypes, which is very valuable for improving the immunotherapeutic efficacy by properly selecting immune checkpoint inhibitors as well as their optimal intervention timing.